Fig. 4

H3K4me3-RS is a novel predictor for ICB therapy response. A The Kaplan–Meier plot for the overall survival (OS) of the 24 melanoma patients treated with anti-PD-1 [52] with high or low H3K4me3-RS. B The Kaplan–Meier plot for the OS of the 43 melanoma patients [53] treated with anti-PD-1 with high or low H3K4me3-RS. C The Kaplan–Meier plot for the OS of the 41melanoma patients [54] treated with anti-PD-1 or anti-PD-1/anti-CTLA-4 combined therapy with high or low H3K4me3-RS. D–F Waterfall plots and bar plots of ICB therapy response for patients from three cohorts in A–C respectively. In the left waterfall plots, each column represents a patient, the column length represents the H3K4me3-RS values, and the color of the columns indicates the ICB response of the patients. In the right bar chart, the column represents the proportion of non-response (NR), response (R), or complete response/partial response (CR/PR), progressive disease (PD), and stable disease (SD) patients after ICB therapy in low H3K4me3-RS and high H3K4me3-RS subgroup. G–I Time-dependent ROC curves for the performance of H3K4me3-RS in predicting ICB responses of patients from the cohorts in A–C respectively. J The Kaplan–Meier plot for the OS of the 336 mUC patients [48] treated with anti-PD-L1 in high or low H3K4me3-RS. K The left bar chart for three TIME type proportions of two patient subgroups in (J). The right box plot for H3K4me3-RS values of patients classified in the three TIME types. L The correlogram for H3K4me3-RS and other immune-related molecular signatures based on the patient cohort in (J). The Blue ellipse represents negative correlation, and the red ellipse represents positive correlation. The value in the box is the Pearson correlation coefficient of two corresponding variables